<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02454010</url>
  </required_header>
  <id_info>
    <org_study_id>FF21101US101</org_study_id>
    <nct_id>NCT02454010</nct_id>
  </id_info>
  <brief_title>A Dose Escalation Study of Radio-labeled Antibody for the Treatment of Advanced Cancer</brief_title>
  <official_title>A Phase 1 Dose-escalation Study of Radio- Labeled Antibody, FF-21101(90Y) for the Treatment of Advanced Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fujifilm Pharmaceuticals U.S.A., Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fujifilm Pharmaceuticals U.S.A., Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and tolerability in subjects who receive
      FF-21101(111In) for dosimetry and FF-21101(90Y) for treatment of advanced solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of radio-labeled FF21101 as measured by number of patients with adverse events leading to discontinuation or number of patients with dose limiting toxicity</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients achieving overall response using Response Evaluation Criteria in Solid Tumors (RECIST v. 1.1)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Overall response rates are defined as the number of patients achieving a best response of complete response [CR], partial response [PR], stable disease [SD], or progressive disease [PD])</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of patients expressing CDH3 (human cadherin 3/P-cadherin) as a predictor of clinical activity</measure>
    <time_frame>Single sample taken at enrollment</time_frame>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Lowest dose of FF-21101(90Y)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the therapeutic phase subjects in this cohort will receive one dose of radiolabeled FF21101</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2X Lowest dose of FF-21101(90Y)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the therapeutic phase subjects in this cohort will receive one dose of radiolabeled FF21101 that is 2X the lowest dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3X Lowest dose of FF-21101(90Y)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the therapeutic phase subjects in this cohort will receive one dose of radiolabeled FF21101 that is 3X the lowest dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4X Lowest dose of FF-21101(90Y)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the therapeutic phase subjects in this cohort will receive one dose of radiolabeled FF21101 that is 4X the lowest dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5X Lowest dose of FF-21101(90Y)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the therapeutic phase subjects in this cohort will receive one dose of radiolabeled FF21101 that is 5X the lowest dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FF21101</intervention_name>
    <description>(90Y) radio-labeled FF21101 (therapeutic monoclonal antibody to P-cadherin expressed by the CDH3 gene)</description>
    <arm_group_label>Lowest dose of FF-21101(90Y)</arm_group_label>
    <arm_group_label>2X Lowest dose of FF-21101(90Y)</arm_group_label>
    <arm_group_label>3X Lowest dose of FF-21101(90Y)</arm_group_label>
    <arm_group_label>4X Lowest dose of FF-21101(90Y)</arm_group_label>
    <arm_group_label>5X Lowest dose of FF-21101(90Y)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females ≥ 18 years of age

          -  Histologically or cytologically confirmed advanced solid tumor malignancy, refractory
             or relapsed from prior therapy, or for whom no alternative therapy is available

          -  At least 4 weeks beyond the last chemotherapy (or ≥ 5 half-lives for targeted agents,
             whichever is shorter), radiotherapy, major surgery or experimental treatment and
             recovered from all acute toxicities (≤ Grade 1)

          -  Archival tumor sample available, or be willing to undergo a fresh tumor biopsy, prior
             to study

          -  At least one measurable disease site that meets target lesion requirements

          -  Adequate performance status: Eastern Cooperative Oncology Group (ECOG) ≤ 2

          -  Life expectancy of ≥ 3 months

          -  Adequate hematologic parameters without ongoing transfusional support:

          -  Hemoglobin (Hb) ≥ 10 g/dL

          -  Absolute neutrophil count (ANC) ≥ 1.5 x 10^9 cells/L

          -  Platelets ≥ 150,000 x 10^6 cells/L

          -  Adequate renal and hepatic function:

          -  Creatinine ≤ 1.5x the upper limit of normal (ULN), or calculated creatinine clearance
             ≥ 60 mL/minute x 1.73 m^2 per the Cockcroft-Gault formula

          -  Total bilirubin &lt; 1.5 times ULN unless due to Gilbert's disease

          -  ALT/AST ≤ 2.5 times ULN, or &lt; 5 times ULN for subjects with liver metastases

          -  QT interval corrected for rate (QTc) ≤ 480 msec on the electrocardiogram (ECG)
             obtained at Screening (average of 3 readings)

          -  Negative serum pregnancy test

          -  Ability to provide written informed consent

        Exclusion Criteria:

          -  Previous radioimmunotherapy. Previous antibody-based therapy is allowed as long as ≥
             28 days has elapsed from last dose to study treatment.

          -  Prior radiation to &gt; 30% of the red marrow or to maximal tolerable level for any organ

          -  Serious cardiac condition within the last 6 months

          -  Concomitant medication(s) that may cause QTc prolongation or induce Torsades de
             Pointes, with the exception of antimicrobials that are considered to be essential for
             care of the patient

          -  History of retinal degenerative disease, history of uveitis, history of retinal vein
             occlusion (RVO), or any eye condition that would be considered a risk factor for RVO
             or has medically relevant abnormalities identified on screening ophthalmologic
             examination

          -  Active central nervous system (CNS) malignant disease in subjects with a history of
             CNS malignancy. Subjects with stable, prior, or currently treated brain metastases are
             allowed.

          -  Known positive for human immunodeficiency virus (HIV), hepatitis B virus surface
             antigen (HBsAg) or hepatitis C virus (HCV)

          -  Known autoimmune disease

          -  Active infection requiring intravenous (IV) antibiotic usage within the last week
             prior to the dosimetry portion of the study

          -  Corticosteroid use within 2 weeks of study treatment

          -  Any other medical intervention or other condition which, in the opinion of the
             Principal Investigator, could compromise adherence with study requirements or confound
             the interpretation of study results

          -  Pregnant or breast-feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Study Coordinator</last_name>
    <phone>617-401-2243</phone>
    <email>fphucontact@fujifilm.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Texas M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivek Subbiah, MD</last_name>
      <email>vsubbiah@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Vivek Subbiah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2015</study_first_submitted>
  <study_first_submitted_qc>May 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2015</study_first_posted>
  <last_update_submitted>February 2, 2018</last_update_submitted>
  <last_update_submitted_qc>February 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Immunoconjugates</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

